Stay updated with breaking news from Encore Vision. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Harrow announced the appointments of Adrienne Graves, Ph.D., and Lauren Silvernail to the Company?s Board of Directors, effective immediately. Harrow?s Board now consists of six members. Dr. Adrienne...
The former TechFW company was acquired in 2022, but not before the new technology breathed life into the peptide industry.
NVS earnings call for the period ending September 30, 2022.
ONL Therapeutics, Inc., an Ann Arbor, Mich.-based biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, closed on $46.9m in a Series B financing round. The round included new investors Bios Partners, which led the round, Johnson & Johnson Innovation – JJDC, Inc., Kaitai Capital, PSQ Capital, and Michigan Capital Network Venture Fund III. Existing investors that participated in the round include ONL Therapeutics management, InFocus Capital Partners, ExSight Ventures, the University of Michigan’s Michigan Investment in New Technolo...
ONL Therapeutics Closes $46.9 Million in Series B Financing to Advance ONL1204 into Three Retinal Disease Indications Beyond retinal detachment, lead candidate ONL1204 will also advance into the chronic conditions of glaucoma and dry age-related macular degeneration over the next 24 months December 22, 2020 07:00 ET | Source: ONL Therapeutics ONL Therapeutics Ann Arbor, Michigan, UNITED STATES ANN ARBOR, Mich., Dec. 22, 2020 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protectin...